NCT03249259

The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Seoul National University Bundang Hospital · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

In this study, the investigators are going to investigate the efficacy of choline alfoscerate on improvement of cognitive function assessed by MMSE compared to plaebo.

Detailed description

The investigators will enroll patients with type 2 diabetes whose age is equal to higher than 60, and randomly assigned study drug or placebo at 1:1 ratio. The treatment duration is 6 months and extension study will be continued to 12 months.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Choline alfoscerate	Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
DRUG	Placebo	Treatment duration is 6 months and can be extended to 12 months with participant's agreement.

Timeline

• Start date: 2016-03-10
• Primary completion: 2019-06-30
• Completion: 2019-09-30
• First posted: 2017-08-15
• Last updated: 2019-10-08

Locations

1 site across 1 country: South Korea